Search

Your search keyword '"Sternberg C"' showing total 1,091 results

Search Constraints

Start Over You searched for: Author "Sternberg C" Remove constraint Author: "Sternberg C"
1,091 results on '"Sternberg C"'

Search Results

1. Naming disease states for clinical utility in prostate cancer: a rose by any other name might not smell as sweet

3. Randomized Trial of Five or Two MRI-guided Adaptive Radiotherapy Treatments for Prostate Cancer (FORT)

4. Dosierung, Sicherheit und Pharmakokinetik der Kombinationstherapie mit Darolutamid (DARO), Androgendeprivationstherapie (ADT) und Docetaxel (DOC) bei Patienten mit metastasiertem hormonsensitivem Prostatakarzinom (mHSPC) in der ARASENS Studie

5. Effizienz und Sicherheit von Darolutamid (DARO) in Kombination mit Androgendeprivationstherapie (ADT) und Docetaxel (DOC) nach Krankheitsvolumen und -risiko in der Phase 3 ARASENS Studie

6. Lebensqualität und Patienten-relevante Endpunkte unter Darolutamid-Therapie in der Phase-3-Studie ARASENS

10. 1390P Circulating tumor DNA (ctDNA) and prognosis with PSMA-targeted radionuclide therapy (TRT)

11. 1360MO Quality of life and patient-relevant endpoints with darolutamide in the phase III ARASENS study

12. LBA74 Genomic biomarkers in peripheral blood (PB) from patients (pts) enrolled in the JAVELIN Bladder 100 trial of avelumab first-line (1L) maintenance in advanced urothelial carcinoma (aUC)

13. 1746P Disease-free survival (DFS) and distant metastasis-free survival (DMFS) as surrogates for overall survival (OS) in adjuvant treatment of muscle-invasive bladder cancer (MIBC)

14. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC)

15. A randomized, double-blind, placebo-controlled phase II study of maintenance therapy with tasquinimod in patients with metastatic castration-resistant prostate cancer responsive to or stabilized during first-line docetaxel chemotherapy

23. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015

29. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

30. Plasma tumor gene conversions after one cycle abiraterone acetate for metastatic castration-resistant prostate cancer: a biomarker analysis of a multi-center international trial.

31. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study.

32. Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study

34. Erratum: Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC) (Annals of Oncology (2018) 29(2) (361–369), (S0923753419350392), (10.1093/annonc/mdx692))

37. Prognostic effect of systemic immune-inflammation index (SII) in 987 patients with advanced/metastatic urinary tract carcinoma (mUTC) treated with atezolizumab in the real-world global SAUL study

39. Neutrophil-lymphocyte ratio (NLR) as a prognostic and predictive biomarker in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with cabazitaxel (CBZ) vs abiraterone or enzalutamide in the CARD study

Catalog

Books, media, physical & digital resources